SWOG researchers to present practice-changing research at virtual ASCO 2021 SWOG always brings an impressive portfolio of work to the ASCO annual meeting, said SWOG Chair Charles D. Blanke, MD, and this year I m particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing.
Investigators will present 12 abstracts from SWOG-led or co-led studies and 11 abstracts from studies led by other groups within the National Clinical Trials Network (NCTN).
Results from S1216 will be presented orally by study chair Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah. S1216 compared androgen deprivation therapy (ADT) combined with TAK-700 to the standard treatment of ADT with bicalutamide in patients who had metastatic hormone-sensitive prostate cancer. The study found that adding TAK-700 to ADT lengthened median progression-free survival in these patients and improved prostate-specific
0:43
Traditionally, pancreatic cancer is treated with surgery first and chemotherapy second. But UC Oncologist Dr. Davendra Sohal was looking for ways to improve outcomes. So in a clinical trial, he and others enrolled 102 early-stage patients and administered chemotherapy before surgery and after. Unfortunately, it did not lead to a cure in more patients than the usual approach, but it has taught us important lessons - how to do it and how to make improvements upon it in future trials, says Sohal.
He explains, We have reached the ceiling of the benefit with chemotherapy, so whether before or after surgery, there is a maximum benefit that we have achieved.
Date Time
MedPage Today: Preop chemotherapy misses mark in pancreatic cancer
Catching pancreatic cancer in earlier stages improves one’s chance for survival, but University of Cincinnati researchers wanted to know if administering chemo before surgery in some patients, in addition to after, would make a difference.
Traditionally, pancreatic cancer is treated with surgery first and chemotherapy second. But Davendra Sohal, MD, associate professor of medical oncology at UC and medical oncologist with UC Health, was looking for ways to improve outcomes. So in a clinical trial, he and others enrolled 102 early-stage patients and administered chemotherapy before surgery and after.
E-Mail
Credit: University of Cincinnati
PORTLAND, OR - A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in
JAMA Oncology.
While the trial findings did not show a direct patient benefit, they do show that it s possible to safely administer chemotherapy prior to pancreatic cancer surgery. They also pave the way for better treatment testing for this notorious killer. With no symptoms in the early stages, and few effective therapies, pancreatic cancer is the fourth-most deadly cancer type in the United States. According to the American Cancer Society, only 20 percent of pancreatic cancer patients are alive one year after diagnosis. After five years, only about 7 percent are alive.